These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18234531)

  • 21. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia.
    Drinkard BE; Keyser RE; Paul SM; Arena R; Plehn JF; Yanovski JA; Di Prospero NA
    Arch Phys Med Rehabil; 2010 Jul; 91(7):1044-50. PubMed ID: 20599042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients.
    Artuch R; Aracil A; Mas A; Monrós E; Vilaseca MA; Pineda M
    Neuropediatrics; 2004 Apr; 35(2):95-8. PubMed ID: 15127307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
    Di Prospero NA; Sumner CJ; Penzak SR; Ravina B; Fischbeck KH; Taylor JP
    Arch Neurol; 2007 Jun; 64(6):803-8. PubMed ID: 17562928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported outcomes in Friedreich's ataxia after withdrawal from idebenone.
    Cook A; Boesch S; Heck S; Brunt E; Klockgether T; Schöls L; Schulz A; Giunti P
    Acta Neurol Scand; 2019 Jun; 139(6):533-539. PubMed ID: 30887496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Introduction. Idebenone in the treatment of Friedreich ataxia.
    Pandolfo M
    J Neurol; 2009 Mar; 256 Suppl 1():1-2. PubMed ID: 19283343
    [No Abstract]   [Full Text] [Related]  

  • 26. Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial.
    Arpa J; Sanz-Gallego I; Rodríguez-de-Rivera FJ; Domínguez-Melcón FJ; Prefasi D; Oliva-Navarro J; Moreno-Yangüela M; Pascual-Pascual SI
    Cerebellum; 2013 Oct; 12(5):713-20. PubMed ID: 23625326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
    Parkinson MH; Schulz JB; Giunti P
    J Neurochem; 2013 Aug; 126 Suppl 1():125-41. PubMed ID: 23859348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial.
    Arpa J; Sanz-Gallego I; Rodríguez-de-Rivera FJ; Domínguez-Melcón FJ; Prefasi D; Oliva-Navarro J; Moreno-Yangüela M
    Acta Neurol Scand; 2014 Jan; 129(1):32-40. PubMed ID: 23668357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idebenone in Friedreich ataxia and Leber's hereditary optic neuropathy: close mechanisms, similar therapy?
    Schiff M; Rustin P
    Brain; 2016 Jul; 139(Pt 7):e39. PubMed ID: 27095078
    [No Abstract]   [Full Text] [Related]  

  • 30. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia.
    Hausse AO; Aggoun Y; Bonnet D; Sidi D; Munnich A; Rötig A; Rustin P
    Heart; 2002 Apr; 87(4):346-9. PubMed ID: 11907009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study.
    Rustin P; von Kleist-Retzow JC; Chantrel-Groussard K; Sidi D; Munnich A; Rötig A
    Lancet; 1999 Aug; 354(9177):477-9. PubMed ID: 10465173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia.
    Rustin P; Rötig A; Munnich A; Sidi D
    Free Radic Res; 2002 Apr; 36(4):467-9. PubMed ID: 12069112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring cardiac function during idebenone therapy in Friedreich's ataxia.
    Giovanni DS; Valeria P; Bahaa F; Majid AF
    Curr Pharm Des; 2015; 21(4):479-83. PubMed ID: 25483949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
    Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
    Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
    Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring of idebenone treatment in patients with Friedreich's ataxia by high-pressure liquid chromatography with electrochemical detection.
    Artuch R; Colomé C; Vilaseca MA; Aracil A; Pineda M
    J Neurosci Methods; 2002 Mar; 115(1):63-6. PubMed ID: 11897364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial.
    Mariotti C; Fancellu R; Caldarazzo S; Nanetti L; Di Bella D; Plumari M; Lauria G; Cappellini MD; Duca L; Solari A; Taroni F
    Mov Disord; 2012 Mar; 27(3):446-9. PubMed ID: 22411849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.
    Rustin P; Bonnet D; Rötig A; Munnich A; Sidi D
    Neurology; 2004 Feb; 62(3):524-5; author reply 525; discussion 525. PubMed ID: 14872056
    [No Abstract]   [Full Text] [Related]  

  • 39. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial.
    Lynch DR; Willi SM; Wilson RB; Cotticelli MG; Brigatti KW; Deutsch EC; Kucheruk O; Shrader W; Rioux P; Miller G; Hawi A; Sciascia T
    Mov Disord; 2012 Jul; 27(8):1026-33. PubMed ID: 22744651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic evaluation of idebenone.
    Becker C; Bray-French K; Drewe J
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1437-44. PubMed ID: 20955109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.